PMX-DHP for COVID-19

Phase 2

• Conditions: COVID-19; D000073640

• Registration Number: JPRN-jRCTs032200131
• Lead Sponsor: Izumi Shinnyuu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-09-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1)Dyspnea that cannot be explained by other diseases (heart failure, renal failure, etc.)
2)SARS-CoV-2 infection has been diagnosed by PCR or LAMP within 1 week
3)chest image shows pneumonia
4)P/F ratio is 300 or less, or SpO2 93% (room air) or less
5)Applicable to any of the following in the eight-category evaluation *
4, hospitalized, requiring supplemental oxygen
5. hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both
6. requiring invasive mechanical ventilation
6)16 years or older
7)Have written consent from the patient or legal representative

Exclusion Criteria

1)Patients with severe progression of multiple organ failure
2) P/F ratio is 100 or less
3)implementing ECMO
4)hospitalized for more than 15 days
5)platelet count of 20,000 /microL or less
6)received cytotoxic or biological treatment within 4 weeks before consent
7)received TNF inhibitor within 2 weeks before consent
8)received recovering plasma or intravenous immunoglobulin against COVID-19
9) A person whose inclusion in the research is deemed inappropriate by the principal investigator or sub-researcher

Study & Design

• Study Type: Interventional
• Study Design: Not specified